Skip to main content
letter
. 2022 Aug 6;54(6):802–805. doi: 10.1016/j.pathol.2022.07.002

Table 1.

Clinical overview and management of patients with autoimmune haemolytic anaemia following COVID-19 vaccinations

Case no. Age (years) Sex Underlying malignancy Vaccine received Time from vaccination to admission Hb on presentation (g/L) Bilirubin on presentation (mcmol/L) LDH on presentation (U/L) DAT Management Hb response (g/L)
1 76 M Chronic lymphocytic leukaemia ChAdOx1nCoV-19 4 days 59 97 835 IgG (–);
C3d (+)

  • First line:

  • -

    RBC transfusion

  • -

    Prednisolone 1 mg/Kg

  • -

    IVIg

  • Second line at relapse:

  • -

    RBC transfusion

  • -

    Prednisolone 1 mg/Kg

  • -

    IVIg

 112
2 49 M Chronic lymphocytic leukaemia BNT162b2 4 days 39 87 685 IgG (+);
C3d (+)

  • First line:

  • -

    RBC transfusion

  • -

    Prednisolone 1 mg/Kg

 123
3 83 F Splenic marginal zone lymphoma ChAdOx1nCoV-19 30 days 57 50 2124 IgG (+);
C3d (+)

  • First line:

  • -

    RBC transfusion

  • -

    IVIg

  • -

    Prednisolone 1 mg/kg

  • Second line at relapse:

  • -

    Chemo-immunotherapy (R-CVP)

 117
4 64 M Chronic lymphocytic leukaemia ChAdOx1nCoV-19 37 days 55 39 488 IgG (+);
C3d (–)

  • First line:

  • -

    RBC transfusion

  • -

    Prednisolone 1 mg/kg

  • Second line at relapse:

  • -

    Rituximab ×4 doses

 123

DAT, direct antiglobulin testing; F, female; Hb, haemoglobin; IVIg, intravenous immunoglobulin; LDH, lactate dehydrogenase; M, male; RBC, red blood cell; R-CVP, rituximab cyclophosphamide vincristine prednisolone.